Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Shoji Tokunaga"'
Autor:
Hiroshi Ishii, Yoichi Nakanishi, Ryo Torii, Makoto Yoshida, Isamu Okamoto, Masaki Fujita, Kazunori Tobino, Masayuki Kawasaki, Eiji Harada, Takashige Maeyama, Naoki Hamada, Masaki Okamoto, Kazuhiro Yatera, Shohei Takata, Kazuya Tsubouchi, Shoji Tokunaga, Katsuyuki Ichiki, Yasuhiko Kitasato, Satoru Kawakami, Taishi Harada, Hiroshi Wataya, Masashi Komori, Yuichi Mizuta, Hidetake Yabuuchi
Publikováno v:
BMJ Open Respiratory Research, Vol 10, Iss 1 (2023)
Objective Few prospective cohort studies with relatively large numbers of patients with non-idiopathic pulmonary fibrosis (non-IPF) of idiopathic interstitial pneumonia (IIP) have been described. We aimed to assess disease progression and cause of de
Externí odkaz:
https://doaj.org/article/da0f29146c624bcfb66096242d58ed0d
Autor:
Toshifumi Fujiwara, Masakazu Kondo, Hisakata Yamada, Akihisa Haraguchi, Kenjiro Fujimura, Koji Sakuraba, Satoshi Kamura, Jun-ichi Fukushi, Hisaaki Miyahara, Yasushi Inoue, Tomomi Tsuru, Toshihide Shuto, Seiji Yoshizawa, Eiichi Suematsu, Tomoya Miyamura, Masahiro Ayano, Hiroki Mitoma, Yojiro Arinobu, Hiroaki Niiro, Masanobu Ohishi, Akie Hirata, Shoji Tokunaga, Atsushi Takada, Daisuke Hara, Hidetoshi Tsushima, Yukio Akasaki, Satoshi Ikemura, Takuya Sueishi, Masakazu Toya, Takahide Sakuragi, Tomoko Tsutsui, Kazuhiro Kai, Shinkichi Arisumi, Yasuharu Nakashima
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-15 (2022)
Abstract Background To further improve rheumatoid arthritis (RA) treatment, it is necessary to understand each RA patient’s satisfaction and to identify the factors affecting their satisfaction. Despite the rise in medical costs for RA, little is k
Externí odkaz:
https://doaj.org/article/5da7eb72e7764e788a48b71d8a27b07d
Autor:
Tomoshi Tsuchiya, Keitaro Matsumoto, Takuro Miyazaki, Ryoichiro Doi, Shoji Tokunaga, Hiroyuki Yamaguchi, Koichi Tomoshige, Hironosuke Watanabe, Takeshi Nagayasu, Kenji Sugio
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background The current standard postoperative treatment for stage II-IIIA non-small cell lung cancer (NSCLC) is a regimen of platinum doublet adjuvant chemotherapy. These regimens, which are the same as for solid NSCLC tumors, often cause se
Externí odkaz:
https://doaj.org/article/84b0e6da558a4fb98bc537863e8f00a2
Autor:
Tomoshi Tsuchiya, Ryotaro Kamohara, Masashi Muraoka, Takeshi Nagayasu, Sho Saeki, Mitsuhiro Takenoyama, Makoto Suzuki, Kazuo Inada, Shoji Tokunaga, Tomayoshi Hayashi, Shogo Urabe, Takaomi Koga, Shinji Akamine, Kenji Sugio
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Lymphovascular invasion (LVI), which includes vascular or lymphatic invasions, is a representative prognostic factor even in patients with resected stage IA non-small cell lung cancer (NSCLC). Because tegafur-uracil is effective o
Externí odkaz:
https://doaj.org/article/6f5c1773999b475b844c5c01eaf8e53c
Publikováno v:
BMC Anesthesiology, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Although propofol is a common anesthetic agent for the induction of general anesthesia, hemodynamic fluctuations are occasionally prominent during induction/intubation. The aims of this study were to determine the influential fact
Externí odkaz:
https://doaj.org/article/6062b183e326433cb068cafab624a3ec
Autor:
Hiroshi Saeki, Yasunori Emi, Eiji Oki, Shoji Tokunaga, Yoshihiro Kakeji, Yoshito Akagi, Hideo Baba, Eishi Baba, Yoshihiko Maehara, Kyushu Study group of Clinical Cancer (KSCC)
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Oxaliplatin + S-1 is a recognized treatment regimen in Japan, but there are no Japanese clinical data on an oxaliplatin dose of 130 mg/m2. The current research involves a single-arm, prospective, phase II clinical trial to examine
Externí odkaz:
https://doaj.org/article/cf2a039747f043699b3ba915d3e422a4
Autor:
Atsushi Kimura, Yoshihiro Matsumoto, Yoshifumi Wakata, Akiko Oyamada, Masanobu Ohishi, Toshifumi Fujiwara, Ko Ikuta, Kuniyoshi Tsuchiya, Naohisa Tayama, Shinji Tomari, Hisaaki Miyahara, Takao Mae, Toshihiko Hara, Taichi Saito, Takeshi Arizono, Kozo Kaji, Taro Mawatari, Masami Fujiwara, Riku Sakimura, Kunichika Shin, Kenichi Ninomiya, Kazutoshi Nakaie, Yasuaki Antoku, Shoji Tokunaga, Naoki Nakashima, Yukihide Iwamoto, Yasuharu Nakashima
Publikováno v:
Journal of Orthopaedic Surgery, Vol 27 (2019)
Purpose: Fragility hip fractures (FHFs) are associated with a high risk of mortality, but the relative contribution of various factors remains controversial. This study aimed to evaluate predictive factors of mortality at 1 year after discharge in Ja
Externí odkaz:
https://doaj.org/article/b81e356c328d4bcc81665f381e35d227
Autor:
Yoshifumi Miura, MD, Hiroshi Noguchi, MD, PhD, Yasuhiro Okabe, MD, Kosuke Masutani, MD, PhD, Shoji Tokunaga, PhD, Masafumi Nakamura, MD, PhD
Publikováno v:
Transplantation Direct, Vol 5, Iss 2, p e423 (2019)
Background. The risk of cardiovascular events remains after kidney transplantation (KT). Abnormal glucose metabolism and hyperlipidemia contribute partly to this risk. Among angiotensin II type-1 receptor blockers, telmisartan alone has been shown to
Externí odkaz:
https://doaj.org/article/ab89e0a4a5964d1f96095421d956d5bb
Publikováno v:
International Journal of General Medicine, Vol 2009, Iss default, Pp 163-170 (2009)
Kouichi Yoshimasu1, Tetsuya Kondo2,4, Shoji Tokunaga3, Yoshio Kanemitsu2, Hideyo Sugahara2, Mariko Akamine2, Kanichiro Fujisawa2, Kazuhisa Miyashita1, Chiharu Kubo21Department of Hygiene, School of Medicine, Wakayama Medical University, Wakayama, Jap
Externí odkaz:
https://doaj.org/article/2b8ed3885ca140f39fd79b8592904360
Autor:
Hideyuki Harada, Haruyasu Murakami, Junichi Shimizu, Kazuhiko Nakagawa, Yoshikazu Hasegawa, Haruko Daga, Shoji Tokunaga, Nobuyuki Yamamoto, Hidetoshi Hayashi, Terufumi Kato, Yasumasa Nishimura, Hiroaki Akamatsu, Young Hak Kim
Publikováno v:
Journal of Thoracic Oncology. 16:1745-1752
Introduction About 10% of patients with locally advanced NSCLC (LA-NSCLC) harbor EGFR mutation and recent reports suggested the declined benefit with an immune checkpoint inhibitor in this population. The attempt that introduces EGFR tyrosine kinase